Although these studies suggest that the dysregulation of CCN1 is tightly associated with ALI and BPD, the development of future therapeutics to target CCN1 in the treatment of these diseases will only become a reality once the exact role of CCN1 and the basic mechanisms by which it promotes these pathologies will be identified. This evidence concerns the gene CCN1 and acute respiratory distress syndrome.